China Probes 60 Drugmakers in Effort to Curb Drug Prices

China’s top economic planning agency is investigating the costs and prices of drugmakers including GlaxoSmithKline Plc, Merck & Co., Novartis AG and Baxter International Inc. to improve the pricing system for medicines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.